Engineering Escherichia coli Nissle 1917 as a microbial chassis for therapeutic and industrial applications

Biotechnol Adv. 2023 Oct:67:108202. doi: 10.1016/j.biotechadv.2023.108202. Epub 2023 Jun 19.

Abstract

Genetically engineered microbes, especially Escherichia coli, have been widely used in the biosynthesis of proteins and metabolites for medical and industrial applications. As a traditional probiotic with a well-established safety record, E. coli Nissle 1917 (EcN) has recently emerged as a microbial chassis for generating living therapeutics, drug delivery vehicles, and microbial platforms for industrial production. Despite the availability of genetic tools for engineering laboratory E. coli K-12 and B strains, new genetic engineering systems are still greatly needed to expand the application range of EcN. In this review, we have summarized the latest progress in the development of genetic engineering systems in EcN, as well as their applications in the biosynthesis and delivery of valuable small molecules and biomacromolecules of medical and/or industrial interest, followed by a glimpse of how this rapidly growing field will evolve in the future.

Keywords: 'Suicide' systems; Bacterial ghosts; CRISPR-Cas; Escherichia coli Nissle 1917; Light-controlled gene expression; Living therapeutics; Minicells.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Delivery Systems*
  • Escherichia coli* / genetics
  • Escherichia coli* / metabolism
  • Genetic Engineering